Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GH Therapy in Partial GHD Adolescents : Evaluation of Efficacy Based on Body Composition and Comparison of 2 Different Doses of Genotonorm®. Open-Label, Randomised, Comparative, Controlled, Parallel-Group, Multi-Center Phase IIIB Clinical Trial.

NCT00156143 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00156143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00156143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GH Therapy in Partial GHD Adolescents : Evaluation of Efficacy Based on Body Composition and Comparison of 2 Different Doses of Genotonorm®. Open-Label, Randomised, Comparative, Controlled, Parallel-Group, Multi-Center Phase IIIB Clinical Trial.
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2002
Completion date
April 30, 2005
Enrollment
90
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

growth hormone deficiency